News Shine rubs off Argenx after Vyvgart Hytrulo fails trial Argenx has been riding high of late thanks to buoyant sales growth for its Vyvgart therapy for muscle-wasting disease generalised myasthenia gravis (gMG), but a failed pha
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face